A review of the anti-inflammatory properties of clindamycin in the treatment of acne vulgaris

Cutis

Volumn 85, Issue 1, 2010, Pages 15-24

  Del Rosso, James Q ^a   Schmidt, Nicholas F ^b  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; CLINDAMYCIN;

ACNE VULGARIS; HUMAN; INFLAMMATION; INTRADERMAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; REVIEW;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; CLINDAMYCIN; HUMANS; INFLAMMATION;

EID: 77949901138     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (99)

1. Berson DS, Shalita AR. The treatment of acne: the role of combination therapies. J Am Acad Dermatol. 1995;32 (5, pt 3):S31-S41.
2. Zouboulis CC, Derumeaux L, Decroix J, et al. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation applied once daily and a clindamycin formulation applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol. 2000;143:498-505.
3. Richter JR, Förström LR, Kiistala UO, et al. Efficacy of the fixed 1.2% clindamycin phosphate, 0.025% tretinoin gel formulation (Velac) and a proprietary 0.025% tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol. 1998;11: 227-233.
4. Gollnick HP, Zouboulis CC, Akamatsu H, et al. Pathogenesis and pathogenesis related treatment of acne. J Dermatol. 1991;18:489-499.
5. Cunliffe WJ. The sebaceous gland and acne-40 years on. Dermatology. 1998;196:9-15.
6. Toyoda M, Morohashi M. Pathogenesis of acne. Med Electron Microsc. 2001;34:29-40.
7. Zouboulis CC, Piquero-Martin J. Update and future of systemic acne treatment. Dermatology. 2003;206:37-53.
8. Jappe U. Pathological mechanisms of acne with special emphasis on Propionibacterium acnes and related therapy. Acta Derm Venereol. 2003;83:241-248.
9. Hoeffler U. Enzymatic and hemolytic properties of Propionibacterium acnes and related bacteria. J Clin Microbiol. 1977;6:555-558.
10. Van Vlem B, Vanholder R, De Paepe P, et al. Immunomodulating effects of antibiotics: literature review. Infection. 1996;24:275-291.
11. Ingham E, Holland KT, Gowland G, et al. Purification and partial characterization of an acid phosphatase (EC 3.1.3.2) produced by Propionibacterium acnes. J Gen Microbiol. 1980;118:59-65.
12. Puhvel S, Reisner RM. The production of hyaluronidase (hyaluronate lyase) by Corynebacterium acnes. J Invest Dermatol. 1972;58:66-70.
13. Holland KT, Aldana O, Bojar RA, et al. Propionibacterium acnes and acne. Dermatology. 1998;196:67-68.
14. Burkhart CG, Burkhart CN, Lehmann PF. Acne: a review of immunologic and microbiologic factors. Postgrad Med J. 1999;75:328-331.
15. Thomsen RJ, Stranieri A, Knutson D. Topical clindamycin treatment of acne. Arch Dermatol. 1980;116: 1031-1034.
16. Farrar MD, Ingham E, Holland KT. Heat shock proteins and inflammatory acne vulgaris: molecular cloning, overexpression and purification of a Propionibacterium acnes GroEL and DnaK homologue. FEMS Microbiol Lett. 2000;191:183-186.
17. Graham GM, Farrar MD, Cruse-Sawyer JE, et al. Proinflammatory cytokine production by human keratinocytes stimulated with Propionibacterium acnes and P acnes GroEL. Br J Dermatol. 2004;150:421-428.
18. Koreck A, Pivarcsi A, Dobozy A, et al. The role of innate immunity in the pathogenesis of acne. Dermatology. 2003;206:96-105.
19. Bhambri S, Del Rosso JQ, Bhambri A. Pathogenesis of acne vulgaris: recent advances. J Drugs Dermatol. 2009;7:615-618.
20. Harper JC, Thiboutot DM. Pathogenesis of acne: recent research advances. Adv Dermatol. 2003;19:1-10.
21. Puhvel SM, Sakamoto M. The chemoattractant properties of comedonal components. J Invest Dermatol. 1978;71: 324-329.
22. Puhvel SM, Sakamoto M. Cytotaxin production by comedonal bacteria. J Invest Dermatol. 1980;74:36-40.
23. Lee WL, Shalita AR, Sunthralingam K, et al. Neutrophil chemotaxis to Propionibacterium acnes lipase and its inhibition. Infect Immun. 1982;35:71-78.
24. Webster GF, Leyden JJ. Characterization of serumindependent polymorphonuclear leukocyte chemotactic factors produced by Propionibacterium acnes. Inflammation. 1980;4:261-271.
25. Webster GF. Inflammation in acne vulgaris. J Am Acad Dermatol. 1995;33(2, pt 1):247-253.
26. Douthwaite S. Interaction of the antibiotics clindamycin and lincomycin with Escherichia coli 23S ribosomal RNA. Nucleic Acids Res. 1992;20:4717-4720.
27. Webster GF, Leyden JJ, McGinley KJ, et al. Suppression of polymorphonuclear leukocyte chemotactic factor production in Propionibacterium acnes by subliminal inhibitory concentrations of tetracycline, ampicillin, minocycline and erythromycin. Antimicrob Agents Chemother. 1982;21:770-772.
28. Brown SK, Shalita AR. Acne vulgaris. Lancet. 1998; 351:1871-1876.
29. Zouboulis CC. Acne: current aspects on pathology and treatment. Dermatol Experiences. 1999;1: 6-37.
30. Piquero-Martin J. Acne Manejo Racional. 3rd ed. Caracas, Venezuela: Corpografica; 2000.
31. Stienhoff M, Luger TA. The skin cytokine network. In: Bos JD, ed. Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology. 3rd ed. Boca Raton, FL: CRC Press; 2005:349-372.
32. Pastore S, Cavani A, Albanesi C, et al. Chemokines of human skin. In: Bos JD, ed. Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology. 3rd ed. Boca Raton, FL: CRC Press; 2005:373-392.
33. Zouboulis CC. Is acne vulgaris a genuine inflammatory disease? Dermatology. 2001;203:277-279.
34. Akamatsu H, Tomita T, Horio T. Effects of Roxithromycin on the production of lipase and neutrophil chemotactic factor by Propionibacterium acnes. Dermatology. 2002;204:277-280.
35. Gribbon EM, Shoesmith JG, Cunliffe WJ, et al. The microaerophily and photosensitivity of Propionibacterium acnes. J Appl Bacteriol. 1994;77:583-590.
36. Kjeldstad B, Johnsson A, Sandberg S, et al. Influence of pH on porphyrin production in Propionibacterium acnes. Arch Dermatol Res. 1984;276:396-400.
37. Holland KT. Nutrition of cutaneous resident microorganisms. In: Noble WC, ed. The Skin Microflora and Microbial Skin Disease. Cambridge, England: Cambridge University Press; 1993:33-72.
38. Luger TA, Schwarz T. Evidence for an epidermal cytokine network. J Invest Dermatol. 1990;95:1005-1011.
39. Ansel J, Perry P, Brown J, et al. Cytokine modulation of keratinocyte cytokines. J Invest Dermatol. 1990;94 (suppl 6):101S-107S.
40. Ingham E, Eady EA, Goodwin CE, et al. Pro-inflammatory levels of interleukin-1a-like bioactivity are present in the majority of open comedones in acne vulgaris. J Invest Dermatol. 1992;98:895-901.
41. Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of Propionibacterium acnes: implications for chronic inflammatory acne. Infect Immun. 1995;63:3158-3165.
42. Kock A, Schwarz T, Kirnbauer R, et al. Human keratinocytes are a source for tumor necrosis factor a: evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light. J Exp Med. 1990;172: 1609-1614.
43. Kupper TS. The activated keratinocyte: a model for inducible cytokine production by non-bone marrow-derived cells in cutaneous inflammatory and immune responses. J Invest Dermatol. 1990;94(suppl 6):146S-150S.
44. Kim J, Ochoa M, Krutzik S, et al. Activation of tolllike receptor 2 in acne triggers inflammatory cytokine responses. J Immunol. 2002;169:1535-1541.
45. Chen Q, Koga T, Uchi H, et al. Propionibacterium acnes-induced IL-8 production may be mediated by NF-κB activation in human monocytes. J Dermatol Sci. 2002;29:97-103.
46. Kuwahara K, Kitazawa T, Kitagaki H, et al. Nadifloxacin, an antiacne quinolone antimicrobial, inhibits the production of proinflammatory cytokines by human peripheral mononuclear cells and normal human keratinocytes. J Dermatol Sci. 2005;38:47-55.
47. Jappe U, Ingham E, Henwood J, et al. Propionibacterium acnes and inflammation in acne; P acnes has T-cell mitogenic activity. Br J Dermatol. 2002;146: 202-209.
48. Jeremy AH, Holland DB, Roberts SG, et al. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol. 2003;121:20-27.
49. Norris JFB, Cunliffe WJ. A histological and immunological study of early acne lesions. Br J Dermatol. 1988;118: 651-659.
50. Liu PT, Krutzok SR, Kim J, et al. Cutting edge: all-transretinoic acid downregulates TLR2 expression and function. J Immunol. 2005;174:2467-2470.
51. Webster GF, Leyden JJ, Tsai CC, et al. Polymorphonuclear leukocyte lysosomal release in response to Propionibacterium acnes in vitro and its enhancement by sera from patients with inflammatory acne. J Invest Dermatol. 1980;74:398-401.
52. Webster GF, Kligman AM. A method for the assay of inflammatory acne of inflammatory mediators in follicular casts. J Invest Dermatol. 1979;73:266-268.
53. Miyachi Y, Yoshioka A, Imamura S, et al. Effect of antibiotics on the generation of reactive oxygen species. J Invest Dermatol. 1986;86:449-453.
54. Akamatsu H, Komura J, Miyachi Y, et al. Suppressive effects of linoleic acid on neutrophil oxygen metabolism and phagocytosis. J Invest Dermatol. 1990;95: 271-274.
55. Webster GF, McGinley KJ, Leyden JJ. Inhibition of lipase production in Propionibacterium acnes by sub-minimalinhibitory concentrations of tetracycline and erythromycin. Br J Dermatol. 1981;104:453-457.
56. Akamatsu H, Kurokawa I, Nishijima S, et al. Inhibition of neutrophil chemotactic factor production in comedonal bacteria by subminimal inhibitory concentrations of erythromycin. Dermatology. 1992; 185:41-43.
57. Camisa C, Eisenstat B, Ragaz A, et al. The effects of retinoids on neutrophil function in vitro. J Am Acad Dermatol. 1982;6(4, pt 2)(suppl):620-629.
58. Akamatsu H, Horio T. The possible role of reactive oxygen species generated by neutrophils in mediating acne inflammation. Dermatology. 1998;196:82-85.
59. Zouboulis CC. Exploration of retinoid activity and the role of inflammation in acne: issues affecting the future directions for acne therapy. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):63-67.
60. Bray MA. Retinoids are potent inhibitors of the generation of rat leukocyte leukotriene B4-like activity in vitro. Eur J Pharmacol. 1984;98:61-67.
61. Shalita AR, Wei-Li L. Inflammatory acne. Dermatol Clin. 1983;1:361-364.
62. Massey A, Mowbray JF, Noble WC. Complement activation by Corynebacterium acnes. Br J Dermatol. 1978;98: 583-584.
63. Webster GF, Leyden JJ, Norman ME, et al. Complement activation in acne vulgaris: in vitro studies with Propionibacterium acnes and Propionibacterium granulosum. Infect Immun. 1978;22:523-529.
64. Burkhart CG, Cantrill J, Butcher CL, et al. Propionibacterium acnes: interaction with complement and development of an enzyme-linked immunoassay for the detection of antibody. Int J Dermatol. 1999;38:200-203.
65. Millikan LE. The rationale for using a topical retinoid for inflammatory acne. Am J Clin Dermatol. 2003;4: 75-80.
66. Czernielewski J, Michel S, Bouclier M, et al. Adapalene biochemistry and the evolution of a new topical retinoid for treatment of acne. J Eur Acad Dermatol Venereol. 2001;15(suppl 3):5-12.
67. Gille J, Paxton LL, Lawley TJ, et al. Retinoic acid inhibits the regulated expression of vascular cell adhesion molecule-1 by cultured dermal microvascular endothelial cells. J Clin Invest. 1997;99:492-500.
68. Fumarulo R, Conese M, Riccardi S, et al. Retinoids inhibit the respiratory burst and degranulation of stimulated human polymorphonuclear leukocytes. Agents Actions. 1991;34:339-344.
69. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol. 1997;36(6, pt 2):S96-S103.
70. Vasquez D. Inhibitors of Protein Biosynthesis. Berlin, Germany: Springer-Verlag; 1979.
71. Gemmell CG. Interactions between clindamycin and immune function. Rev Contemp Pharmacother. 1992;3: 321-327.
72. Tan H. Topical antibacterial treatments for acne vulgaris. Am J Clin Dermatol. 2004;5:79-84.
73. Unkles SE, Gemmell CG. Effect of clindamycin, erythromycin, lincomycin, and tetracycline on growth and extracellular lipase production by propionibacteria in vitro. Antimicrob Agents Chemother. 1982;21:39-43.
74. Pablo GM, Fulton JE Jr. Sebum: analysis by infrared spectroscopy. II. the suppression of free fatty acids by systemically administered antibiotics. Arch Dermatol. 1975;111:734-735.
75. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol. 1978;70:51-55.
76. Akamatsu H, Nishijma S, Takahashi M, et al. Effects of subminimal concentrations of erythromycin, tetracycline, clindamycin, and minocycline on the neutrophil chemotactic factor production in Propionibacterium acnes biotypes 1-5. J Dermatol. 1991;18:247-251.
77. Veringa EM, Lambe DS Jr, Ferguson DA Jr, et al. Enhancement of opsonophagocytosis of Bacteroides spp. by clindamycin in subinhibitory concentrations. J Antimicrob Chemother. 1989;23:577-587.
78. Veringa EM, Verhoef J. Influence of subinhibitory concentrations of clindamycin on opsonophagocytosis of Staphylococcus aureus, a protein-A-dependent process. Antimicrob Agents Chemother. 1986;30:796-797.
79. Milatovic D, Braveny I, Verhoef J. Clindamycin enhances opsonization of Staphylococcus aureus. Antimicrob Agents Chemother. 1983;24:413-417.
80. Gemmell CG, Peterson PK, Schmeling D, et al. Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following growth in the presence of clindamycin. J Clin Invest. 1981;67:1249-1256.
81. Eick S, Pfister W, Fiedler D, et al. Clindamycin promotes phagocytosis and intracellular killing of periodontopathogenic bacteria by crevicular granulocytes: an in vitro study. J Antimicrob Chemother. 2000;46:583-588.
82. Mascellino MT, De Vito ML, Maclean Feeney E, et al. Phagocytosis and killing of A-protein positive Staphylococcus aureus in the presence of low doses of antibiotics. Drugs Exp Clin Res. 1989;15:63-69.
83. Hand WL, Hand DL, King-Thompson NL. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes. Antimicrob Agents Chemother. 1990;34:863-870.
84. Ras GJ, Anderson R, Taylor GW, et al. Clindamycin, erythromycin, and roxithromycin inhibit the proinflammatory interactions of Pseudomonas aeruginosa pigments with human neutrophils in vitro. Antimicrob Agents Chemother. 1992;36:1236-1240.
85. Brinkmann KC, Talati AJ, Akbari RE, et al. Group B streptococci exposed to rifampin or clindamycin (versus ampicillin or cefotaxime) stimulate reduced production of inflammatory mediators by murine macrophages. Pediatr Res. 2005;57:419-423.
86. Webster GF, Toso SM, Hegemann L. Inhibition of a model of in vitro granuloma formation by tetracyclines and ciprofloxacin. Arch Dermatol. 1994;130:748-752.
87. Nakano T, Hiramatsu K, Kishi K, et al. Clindamycin modulates inflammatory-cytokine induction in lipopolysaccharidestimulated mouse peritoneal macrophages. Antimicrob Agents Chemother. 2003;47:363-367.
88. Hirata N, Hiramatsu K, Hishi K, et al. Pretreatment of mice with clindamycin improves survival of endotoxic shock by modulating the release of inflammatory cytokines. Antimicrob Agents Chemother. 2001;45:2638-2642.
89. Kishi K, Hirai K, Hiramatsu K, et al. Clindamycin suppresses endotoxin released by ceftazidime-treated Escherichia coli O55:B5 and subsequent production of tumor necrosis factor-α and interleukin 1β. Antimicrob Agents Chemother. 1999;43:616-622.
90. Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin Infect Dis. 1995;20(suppl 2):S154-S157.
91. Duffield JS. The inflammatory macrophage: a story of Jekyll and Hyde. Clin Sci (Lond). 2003;104:27-38.
92. Hand WL, Hand DL. Influence of pentoxifylline and its derivatives on antibiotic uptake and superoxide generation by human phagocytic cells. Antimicrob Agents Chemother. 1995;39:1574-1579.
93. Dell'Anna ML, Camera E, Picardo M. Free radicals. In: Bos JD, ed. Skin Immune System: Cutaneous Immunology and Clinical Immunodermatology. 3rd ed. Boca Raton, FL: CRC Press; 2005:287-313.
94. Mouser PE, Baker BS, Seaton ED, et al. Propionibacterium acnes-reactive T helper-1 cells in the skin of patients with acne vulgaris [letter]. J Invest Dermatol. 2003;121: 1226-1228.
95. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons learned from clinical studies. Br J Dermatol. 2005;153:395-403.
96. Schlessinger J, Menter A, Gold M, et al. Clinical safety and efficacy studies of a novel formulation combining 1.2% clindamycin phosphate and 0.025% tretinoin for the treatment of acne vulgaris. J Drugs Dermatol. 2007;6:607-615.
97. Rosen T, Waisman M. Topically administered clindamycin in the treatment of acne vulgaris and other dermatologic disorders. Pharmacotherapy. 1981;1:201-205.
98. Shalita AR, Myers JA, Krochmal L, et al. The safety and efficacy of clindamycin phosphate foam 1% versus clindamycin phosphate topical gel 1% for the treatment of acne vulgaris. J Drugs Dermatol. 2005;4:48-56.
99. Gollnick H, Cunliffe W, Berson D, et al; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(suppl 1):S1-S37.